7,053 reports of this reaction
2.8% of all MYCOPHENOLATE MOFETIL reports
#3 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #3 most commonly reported adverse reaction for MYCOPHENOLATE MOFETIL, manufactured by Genentech, Inc.. There are 7,053 FDA adverse event reports linking MYCOPHENOLATE MOFETIL to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 2.8% of all 256,184 adverse event reports for this drug.
MYCOPHENOLATE MOFETIL has an overall safety score of 85 out of 100. Patients taking MYCOPHENOLATE MOFETIL who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is a less commonly reported adverse event for MYCOPHENOLATE MOFETIL, but still significant enough to appear in the safety profile.
In addition to product use in unapproved indication, the following adverse reactions have been reported for MYCOPHENOLATE MOFETIL:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 7,053 FDA reports for MYCOPHENOLATE MOFETIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 2.8% of all adverse event reports for MYCOPHENOLATE MOFETIL, making it one of the most commonly reported side effect.
If you experience product use in unapproved indication while taking MYCOPHENOLATE MOFETIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.